Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma
Journal for ImmunoTherapy of Cancer · 2025
DOI: 10.1136/jitc-2024-010683 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Rotem Leshem und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infection, Immunity and Respiratory Medicine, The University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Melanoma, Programmed Cell Death 1 Receptor, Poly(ADP-ribose) Polymerases, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ribon Therapeutics, Worldwide Cancer Research, Melanoma Research Alliance.
Abstract (Originalsprache)
Background
Programmed cell death 1 (PD-1) signaling blockade by immune checkpoint inhibitors (ICI) effectively restores immune surveillance to treat melanoma. However, chronic interferon-gamma (IFNγ)-induced immune homeostatic responses in melanoma cells contribute to immune evasion and acquired resistance to ICI. Poly ADP ribosyl polymerase 14 (PARP14), an IFNγ-responsive gene product, partially mediates IFNγ-driven resistance. PARP14 inhibition prolongs PD-1 blockade responses in preclinical models, but fails to achieve full tumor clearance, suggesting the involvement of additional resistance mechanisms.
Methods
We identified a robust PARP14 catalytic inhibitor gene signature and evaluated its association with patient survival. Using preclinical models and single-cell RNA sequencing, we investigated immune and tumor cell adaptations to PARP14 inhibition combined with PD-1 blockade.
Results
Combining PARP14 inhibition and PD-1 blockade suppressed tumor-associated macrophages while increasing proinflammatory memory macrophages. Moreover, this combination mitigated the terminal exhaustion of cytotoxic T cells by inducing a quiescent state, thereby preserving functionality. Despite the enhanced immune responses, tumor cells developed adaptive resistance by engaging alternative immune evasion pathways.
Conclusions
Although adaptive resistance mechanisms re-emerge, PARP14 inhibition combined with PD-1 blockade offers a promising strategy to enhance treatment outcomes and overcome ICI resistance in melanoma, as immune cells are primed for further therapeutic interventions that leverage the quiescent state.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infection, Immunity and Respiratory Medicine, The University of Manchester, Manchester, UK.
- Lydia Becker Institute of Immunology and Inflammation, The University of Manchester, Manchester, UK.
- School of Biological Sciences, The University of Manchester, Manchester, UK.
- Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Bioinformatics Core Facility, The University of Manchester, Manchester, UK.
ORCID-Profile: Rotem Leshem, Kieran Neil Sefton, Chun Wai Wong, I-Hsuan Lin, Dervla Tamara Isaac, Mario Niepel, Adam Hurlstone
Förderung
- Ribon Therapeutics
- Worldwide Cancer Research
- Melanoma Research Alliance
- Hong Kong Scholarship for Excellence Scheme
Zitieren
APA
Leshem, R., Sefton, K. N., Wong, C. W., Lin, I. H., Isaac, D. T., Niepel, M., & Hurlstone, A. (2025). Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010683
Vancouver
Leshem R, Sefton KN, Wong CW, Lin IH, Isaac DT, Niepel M, et al. Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010683
BibTeX
@article{Leshem2025,
author = {Leshem, Rotem and Sefton, Kieran Neil and Wong, Chun Wai and Lin, I-Hsuan and Isaac, Dervla Tamara and Niepel, Mario and Hurlstone, Adam},
title = {Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
doi = {10.1136/jitc-2024-010683}
}
EUVIMED